SHANGHAI, Mar. 17, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering patient management, online healthcare
information, professional training and educational services, today
announced the renewal of its partnership with the China Association
for Health Promotion and Education and GlaxoSmithKline
(China) Investment Limited to
continue the medical education program "Pulmonary Arterial
Hypertension Online Course – Connections with Famous Hospitals"
("PAH Project") in 2021.
The PAH Project aims to promote the implementation of the
multidisciplinary treatment model of pulmonary hypertension and
improve doctors' ability to solve clinical problems. In 2020, more
than 200 experts in pulmonary hypertension participated in the PAH
Project, training a total of 10,000 clinicians. In 2021, we expect
increased clinicians to participate in PAH Project to get training for knowledge
updates, skill learning, and experience exchange in pulmonary
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "Compared to the
population base and the number of potential pulmonary hypertension
patients in China, the number of
physicians specializing in the diagnosis and treatment of this
field is very limited. Therefore, our PAH project in 2020 had
received positive response and recognition from the majority of
clinicians. The success of the PAH project brings valuable
experiences for us in educating rare diseases. We believe we will
attract more social and commercial cooperation in promoting rare
diseases education to grow our business further."
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing
China, Zhongchao Inc. is an online provider of healthcare
information is an online
provider of healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. The
Company also offers patient management services under its
"Zhongxun" platform (www.zhongxun.online). More information about
the Company can be found at its investor relations website
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that may
cause the actual results to differ materially from the Company's
expectations discussed in the forward-looking statements. These
statements are subject to uncertainties and risks including, but
not limited to, the following: the Company's goals and
strategies; the Company's future business development; product and
service demand and acceptance; changes in technology; economic
conditions; the growth of the professional training and educational
services market in China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions
in China and the international markets the Company plans
to serve and assumptions underlying or related to any of the
foregoing and other risks contained in reports filed by the Company
with the SEC, the length and severity of the recent
coronavirus outbreak, including its impacts across our business and
operations. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the SEC, which are available for
review at www.sec.gov. The Company undertakes no obligation to
publicly revise these forward–looking statements to reflect events
or circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Pei Xu, CFO
Phone: +86 21-3220-5987
Weitian Group LLC
Phone: +1 718-213-7386
SOURCE Zhongchao Inc.